ArticleFrontiers in nutrition2025
The predictive value of hsCRP/HDL-C ratio for cardiometabolic multimorbidity in middle-aged and elderly people: evidence from a large national cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Neutrophil-to-high-density lipoprotein cholesterol ratio and prevalent cardiometabolic multimorbidity in older adults: an exploratory cross-sectional analysis.BMC endocrine disorders · 2026Article
- Associations between the C-reactive protein-triglyceride-glucose index and its derived indices and the incidence and progression of cardiometabolic multimorbidity in participants with metabolic dysfunction-associated steatotic liver disease: a large-scale prospective cohort study.Cardiovascular diabetology · 2026Article
- Associations between the C-reactive protein-triglyceride glucose index and the incidence and progression trajectory of cardiometabolic multimorbidity: a multi-state model study.Cardiovascular diabetology · 2026Article
- Review
- Associations of CALLY, CLR, and CHR with all-cause mortality in patients receiving maintenance hemodialysis: a two-center retrospective cohort study.Frontiers in endocrinology · 2026Article
- The Systemic Immune-Inflammation Index and High-Sensitivity C-Reactive Protein to High-Density Lipoprotein Cholesterol Ratio Predict Moderate and Severe Coronary Artery Stenosis in Older Patients with Coronary Heart Disease.Clinical interventions in aging · 2026Article
- Clinical Manifestations and Risk Factors of Osteoporosis in Patients with Type 2 Diabetes Mellitus.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease is associated with inflammation and dysregulated lipid metabolism. This study aimed to investigate the predictive value of high-sensitive C-reactive protein to high-density lipoprotein cholesterol ratio (CHR) in assessing the risk of developing cardiometabolic multi-morbidity (CMM) within the Chinese population. Methods: A cohort of 8,187 participants were selected from the China Health and Retirement Longitudinal Study (CHARLS) and divided into four groups based on the quartile of CHR. To evaluate the association between CHR and CMM, we employed multivariable Cox proportional hazards regression, logistic regression, and restricted cubic splines (RCS) analysis. Subgroup analyses and interaction tests were conducted to further explore these relationships. Results: The mean age of the included participants was 58.64 ± 9.66 years, with 53.7% being female. Over a median follow-up period of 109 months, 858 participants (10.5%) were diagnosed with new-onset CMM. The incidence of CMM across CHR quartiles Q1, Q2, Q3, and Q4 were 6.4, 9.4, 12.0, and 14.2%, respectively. Compared to the lowest quartile, the fully adjusted hazard ratio (with 95% confidence intervals) for CMM for quartiles Q2-Q4 were 1.43 (1.14-1.79), 1.67 (1.35-2.07), and 1.91 (1.55-2.37), respectively. Per 0.01 unit increase in CHR correlates with a 38% increase in the risk of CMM (HR = 1.38, 95% CI = 1.08-1.77, Conclusion: A higher CHR was positively associated with the risk of CMM. Our findings suggest that CHR, when considered alongside other risk factors, could serve as a valuable biomarker for identifying individuals at heightened risk of developing CMM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.